Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 82 | PfizerINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | terminated | Phase 1 | 28 | EpicentRx, Inc.INDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT04009460 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Elpiscience Biopharma, Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | terminated | Phase 1 | 33 | Polaris GroupINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01553071 | Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | terminated | Phase 1 | 16 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | terminated | Phase 1 | 27 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04156100 | A Study in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 19 | Agenus Inc.INDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | terminated | Phase 1 / Phase 2 | 11 | Incyte CorporationINDUSTRY | 1 | Feb 28, 2022 | clinicaltrials |
| NCT03739138 | Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | terminated | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Feb 28, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01295697 | Study of EZN-2208 Pediatric Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 32 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02687386 | A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR(ECREST) | terminated | Phase 1 | 9 | Dr David ZieglerOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03665129 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors(STELLAR-001) | terminated | Phase 1 | 73 | Innate PharmaINDUSTRY | 2 | Jan 27, 2022 | clinicaltrials |
| NCT04810208 | Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours | terminated | Phase 1 | 6 | Lidds ABINDUSTRY | 3 | Dec 30, 2021 | clinicaltrials |
| NCT00560716 | A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT02587598 | Study of INCB053914 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 97 | Incyte CorporationINDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT02189174 | Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 3, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT03752177 | A Study of LY3415244 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03403725 | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study(CD205SHUTTLE) | terminated | Phase 1 | 28 | Menarini GroupINDUSTRY | 4 | Sep 28, 2021 | clinicaltrials |
| NCT04111445 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 1 | Adagene IncINDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03471286 | A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT00359294 | A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma | terminated | Phase 1 | 12 | PharmaMarINDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04312282 | The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | terminated | Phase 1 | 93 | Odonate Therapeutics, Inc.INDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT02765165 | Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 26 | Proximagen, LLCINDUSTRY | 2 | Jul 23, 2021 | clinicaltrials |
| NCT02168725 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | terminated | Phase 1 | 26 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03804515 | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | terminated | Phase 1 | 2 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04162301 | A Study of CS3002 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 10 | CStone PharmaceuticalsINDUSTRY | 1 | Apr 15, 2021 | clinicaltrials |
| NCT03992326 | Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors | terminated | Phase 1 | 6 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02587962 | Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors | terminated | Phase 1 / Phase 2 | 34 | MedivirINDUSTRY | 1 | Jan 14, 2021 | clinicaltrials |
| NCT02608125 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 | 45 | Principia Biopharma, a Sanofi CompanyINDUSTRY | 2 | Dec 24, 2020 | clinicaltrials |
| NCT03096340 | Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer | terminated | Phase 1 | 10 | Intezyne Technologies, Inc.INDUSTRY | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01529307 | First in Human Trial of TAS266 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 6 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01064089 | Dose Escalation of HSP990 in Japan/Korea | terminated | Phase 1 | 17 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03976050 | Phase I Study of HL-085 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 4 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Nov 18, 2020 | clinicaltrials |
| NCT02253992 | An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 232 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | terminated | Phase 1 | 41 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01948297 | Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations | terminated | Phase 1 | 77 | Debiopharm International SAINDUSTRY | 5 | Sep 9, 2020 | clinicaltrials |
| NCT03539484 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | terminated | Phase 1 | 26 | Hoffmann-La RocheINDUSTRY | 4 | Sep 3, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT03256331 | Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients | terminated | Phase 1 | 23 | Belx Bio-Pharmaceutical (Taiwan) CorporationINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02648711 | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | terminated | Phase 1 | 41 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2022source: clinicaltrials